Literature DB >> 11122863

Modern management of cancer-related intestinal obstruction.

M P Davis1, C Nouneh.   

Abstract

Malignant associated bowel obstruction remains a common and perplexing problem for patients with advanced gynecologic and gastrointestinal malignancies. The ability to locate and define its cause preoperatively has improved with the advent of computed tomography. Initial clinical experience with half-Fourier acquisition single-shot turbo spin-echo magnetic resonance imaging (HASTE MRI) and virtual colonoscopy is exciting. The surgical approach for primary obstructing colon cancer has become more aggressive, with experienced surgical groups doing one-stage procedures. Yet to be defined are guidelines for surgical management of obstructions occurring in the face of recurrent disease. Stent placement for upper and lower bowel obstructions is an option in nonoperable patients. Pharmacologic symptom management for intestinal obstructions consists of an opioid, an anticholinergic, and an anti-emetic. Octreotide, either alone or added to the original regimen, will palliate symptoms that are resistant to the three-drug combination.

Entities:  

Mesh:

Year:  2000        PMID: 11122863     DOI: 10.1007/s11912-000-0028-6

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  75 in total

1.  Glycopyrrolate: a useful drug in the palliation of mechanical bowel obstruction.

Authors:  M P Davis; A Furste
Journal:  J Pain Symptom Manage       Date:  1999-09       Impact factor: 3.612

2.  Octreotide may prevent definitive intestinal obstruction.

Authors:  S Mercadante; J Kargar; G Nicolosi
Journal:  J Pain Symptom Manage       Date:  1997-06       Impact factor: 3.612

3.  Fast MR imaging and the detection of small-bowel obstruction.

Authors:  F Regan; D P Beall; M E Bohlman; R Khazan; A Sufi; D C Schaefer
Journal:  AJR Am J Roentgenol       Date:  1998-06       Impact factor: 3.959

4.  A randomized controlled trial of local injections of hyaluronidase versus placebo in cancer patients receiving subcutaneous hydration.

Authors:  E Bruera; C M Neumann; E Pituskin; K Calder; J Hanson
Journal:  Ann Oncol       Date:  1999-10       Impact factor: 32.976

5.  Small bowel metastases of malignant melanoma: palliative effect of surgical resection.

Authors:  X S Hao; Q Li; H Chen
Journal:  Jpn J Clin Oncol       Date:  1999-09       Impact factor: 3.019

6.  Contribution of computed tomography to decision making in the management of adhesive small bowel obstruction.

Authors:  V Donckier; J Closset; D Van Gansbeke; M Zalcman; M Sy; J J Houben; J P Lambilliotte
Journal:  Br J Surg       Date:  1998-08       Impact factor: 6.939

Review 7.  Octreotide in malignant intestinal obstruction.

Authors:  H S Pandha; J Waxman
Journal:  Anticancer Drugs       Date:  1996-01       Impact factor: 2.248

8.  The opioid-sparing effects of intravenous ketorolac as an adjuvant analgesic in cancer pain: application in bone metastases and the opioid bowel syndrome.

Authors:  S K Joishy; D Walsh
Journal:  J Pain Symptom Manage       Date:  1998-11       Impact factor: 3.612

9.  Radical resection in obstructing colorectal carcinomas.

Authors:  M Kruschewski; N Runkel; H J Buhr
Journal:  Int J Colorectal Dis       Date:  1998       Impact factor: 2.571

10.  Palliative treatment of malignant colorectal strictures with metallic stents.

Authors:  L Paúl Díaz; I Pinto Pabón; R Fernández Lobato; C Montes López
Journal:  Cardiovasc Intervent Radiol       Date:  1999-01       Impact factor: 2.740

View more
  1 in total

1.  Malignant bowel obstruction: A retrospective clinical analysis.

Authors:  Jia-Hong Chen; Tzu-Chuan Huang; Ping-Ying Chang; Ming-Shen Dai; Ching-Liang Ho; Yeu-Chin Chen; Tsu-Yi Chao; Woei-Yau Kao
Journal:  Mol Clin Oncol       Date:  2013-11-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.